Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced Enzyme Technologies's quarterly market cap
declined
from Sep. 2025 (₹36,440 Mil) to Dec. 2025 (₹33,830 Mil) and
declined
from Dec. 2025 (₹33,830 Mil) to Mar. 2026 (₹28,575 Mil).
Advanced Enzyme Technologies's annual market cap
declined
from Mar. 2024 (₹38,965 Mil) to Mar. 2025 (₹31,265 Mil) and
declined
from Mar. 2025 (₹31,265 Mil) to Mar. 2026 (₹28,575 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Advanced Enzyme Technologies's Enterprise Value for Today is ₹30,079 Mil.
Advanced Enzyme Technologies (NSE:ADVENZYMES) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Advanced Enzyme Technologies Market Cap Related Terms
Advanced Enzyme Technologies Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ADVENZYMES vs LIN, SHW, ECL: Market Cap Comparison
For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Enzyme Technologies Market Cap vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's Market Cap distribution charts can be found below:
* The bar in red indicates where Advanced Enzyme Technologies's Market Cap falls into.
Advanced Enzyme Technologies Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a Market Cap of ₹36,319 Mil as of Aug. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Advanced Enzyme Technologies and its competitors. According to the industry distribution chart, Advanced Enzyme Technologies ranks #741 out of 1631 companies in the Chemicals industry, placing it in the top 45.4%.
Is Advanced Enzyme Technologies' Market Cap too high?
Advanced Enzyme Technologies' current Market Cap is ₹36,319 Mil. Based on the distribution chart, Advanced Enzyme Technologies ranks #741 out of 1631 companies in the Chemicals industry, which is above the industry midpoint. Overall, Advanced Enzyme Technologies has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' Market Cap compare to LIN and SHW?
According to the Chemicals industry distribution chart, Advanced Enzyme Technologies ranks #741 out of 1631 companies for Market Cap. This puts Advanced Enzyme Technologies in the upper half of its industry. The industry median Market Cap is 300.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Chemicals company?
The median Market Cap among Chemicals companies is 300.66, based on 1,631 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Advanced Enzyme Technologies and its competitors. For the Chemicals industry, the median Market Cap is 300.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Enzyme Technologies's current Market Cap is ₹36,319 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹420.89, compared to a current price of ₹324.35 — trading 22.9% below its estimated fair value. The current Market Cap is ₹36,319 Mil. Advanced Enzyme Technologies' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current Market Cap is ₹36,319 Mil as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued.
The current stock price of ₹324.35 is trading 22.9% below its estimated GF Value™ of ₹420.89.
GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.
Key valuation signals for NSE:ADVENZYMES:
Market Cap: ₹36,319 Mil
GF Value™: ₹420.89 vs. price of ₹324.35 (22.9% below fair value)
No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
89GF Score
Get the complete analysis for NSE:ADVENZYMES
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ADVENZYMES has been successfully added to your 
